Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
作者信息
Ottaiano Alessandro, Capuozzo Maurizio, Nasti Guglielmo, Maiolino Piera, De Angelis Valentina, Scala Stefania, Iaffaioli Rosario V
机构信息
Department of Colorectal Oncology at the National Cancer Institute, "G. Pascale" foundation, via M. Semmola Naples, Italy.
出版信息
Front Immunol. 2013 Jan 7;3:409. doi: 10.3389/fimmu.2012.00409. eCollection 2012.
Abstract
摘要
相似文献
1
Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition.
Front Immunol. 2013 Jan 7;3:409. doi: 10.3389/fimmu.2012.00409. eCollection 2012.
2
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Int J Cancer. 2017 Feb 15;140(4):922-929. doi: 10.1002/ijc.30507. Epub 2016 Nov 23.
3
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25.
4
Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Arch Med Res. 2014 Jul;45(5):366-74. doi: 10.1016/j.arcmed.2014.05.004. Epub 2014 May 13.
5
A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.
Eur J Cancer. 2011 Jun;47(9):1343-54. doi: 10.1016/j.ejca.2011.03.031. Epub 2011 May 5.
6
Retreatment with anti-EGFR monoclonal antibodies in metastatic colorectal cancer: Systematic review of different strategies.
Cancer Treat Rev. 2019 Feb;73:41-53. doi: 10.1016/j.ctrv.2018.12.006. Epub 2018 Dec 27.
7
Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.
Pharmacogenomics. 2014 May;15(7):1043-52. doi: 10.2217/pgs.14.66.
8
Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.
Target Oncol. 2010 Mar;5(1):19-28. doi: 10.1007/s11523-010-0138-5. Epub 2010 Apr 11.
9
Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Clin Ther. 2010 Mar;32(3):437-53. doi: 10.1016/j.clinthera.2010.03.012.
10
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742.
本文引用的文献
1
Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.
Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):21046-51. doi: 10.1073/pnas.1218750110. Epub 2012 Dec 3.
2
Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.
J Transl Med. 2012 Nov 21;10:232. doi: 10.1186/1479-5876-10-232.
3
Combination strategies to enhance antitumor ADCC.
Immunotherapy. 2012 May;4(5):511-27. doi: 10.2217/imt.12.38.
4
Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.
Clin Cancer Res. 2011 Sep 1;17(17):5668-73. doi: 10.1158/1078-0432.CCR-11-0239. Epub 2011 Jul 25.
5
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.
Lancet Oncol. 2011 Jun;12(6):594-603. doi: 10.1016/S1470-2045(10)70209-6. Epub 2010 Dec 14.
6
The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.
Oncologist. 2010;15(1):73-84. doi: 10.1634/theoncologist.2009-0167. Epub 2010 Jan 12.
7
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
J Clin Oncol. 2009 Mar 1;27(7):1122-9. doi: 10.1200/JCO.2008.18.0463. Epub 2009 Jan 21.
8
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021.
9
Diversity of human immune system multigene families and its implication in the genetic background of rheumatic diseases.
Curr Med Chem. 2007;14(4):431-9. doi: 10.2174/092986707779941041.
10
A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.
Arthritis Res Ther. 2005;7(6):R1183-8. doi: 10.1186/ar1802. Epub 2005 Aug 11.
Zotero 插件